Compound Detail
CHEMBL1118
DESVENLAFAXINE 💊 Approved Drug
Enter ChEMBL ID:
Free Research Context
This compound will appear in recent viewed items on the research home for this browser.
Research home
View demo workspace
💊 Approved Drug
Basic Information
| ChEMBL ID | CHEMBL1118 |
| Name | DESVENLAFAXINE |
| Phase | Approved |
| Structure Type | MOL |
| InChI Key | KYYIDSXMWOZKMP-UHFFFAOYSA-N |
| Therapeutic | ✓ Yes |
6
Targets
16
Activities
2
Assay Types
5
PK Parameters
20
Publications
9
Known Names
5
Indications
2
Mechanisms
Molecular Properties
263.4
MW (Da)
2.73
ALogP
3
HBA
2
HBD
43.7
PSA (Ų)
0.88
QED
0
Ro5 Violations
4
Rot. Bonds
Drug Information
| Molecule Type | Small molecule |
| First Approval | 2008 |
| Availability | Prescription |
| Chirality | Racemic |
Mechanism of Action
| Mechanism | Action Type | Target | Direct | Efficacy |
|---|---|---|---|---|
| Serotonin transporter inhibitor | INHIBITOR | Sodium-dependent serotonin transporter | ✓ | ✓ |
| Norepinephrine transporter inhibitor | INHIBITOR | Sodium-dependent noradrenaline transporter | ✓ | ✓ |
Indications
Depressive Disorder Depressive Disorder Depressive Disorder, Major Fibromyalgia Hepatitis C, Chronic
ATC Classification
N06AX23
desvenlafaxine
Level 1: NERVOUS SYSTEM
Level 2: PSYCHOANALEPTICS
Drug Warnings
Black Box Warning
psychiatric toxicity
Activity Summary
IC50 12 meas. best 7.77
Ki 4 meas. best 8.39
Target Activity Profile
| Target | Type | Best pChEMBL | Mean pChEMBL | Best (nM) | # Data |
|---|---|---|---|---|---|
| Sodium-dependent serotonin transporter CHEMBL228 | Ki | 8.39 | 8.105 | 4.1 | 2 |
| Sodium-dependent serotonin transporter CHEMBL228 | IC50 | 7.77 | 7.525 | 17.0 | 2 |
| Alpha-1A adrenergic receptor CHEMBL319 | IC50 | 7.22 | 7.22 | 60.0 | 1 |
| Sodium-dependent serotonin transporter CHEMBL313 | IC50 | 6.75 | 6.75 | 180.0 | 1 |
| Sodium-dependent noradrenaline transporter CHEMBL222 | IC50 | 6.27 | 6.045 | 538.0 | 2 |
| Sodium-dependent noradrenaline transporter CHEMBL222 | Ki | 6.17 | 6.17 | 668.0 | 1 |
| Norepinephrine transporter CHEMBL304 | IC50 | 5.94 | 5.94 | 1160.0 | 1 |
| Sodium-dependent dopamine transporter CHEMBL238 | Ki | 5.43 | 5.43 | 3726.0 | 1 |
Pharmacokinetic Data
| Parameter | Value | Units | Species |
|---|---|---|---|
| Fu | 0.45 | - | Mus musculus |
| Fu | 0.99 | - | Mus musculus |
| Fu | 0.35 | - | Rattus norvegicus |
| Fu | 0.89 | - | Rattus norvegicus |
| T1/2 | 11.0 | hr | Homo sapiens |
Activity Data Samples
Top measurements by pChEMBL value
Literature References
| PubMed | DOI | Target Context | # Activities |
|---|---|---|---|
| - | 10.5281/zenodo.13943903 | ADMET | 89 |
| 31158845 | 10.1038/s41586-019-1291-3 | ADMET | 65 |
| 22194678 | 10.1371/journal.pcbi.1002310 | Hepatotoxicity | 14 |
| 22112383 | 10.1124/dmd.111.043083 | ADMET | 8 |
| 22112383 | 10.1124/dmd.111.043083 | Plasma | 6 |
| 22112383 | 10.1124/dmd.111.043083 | Brain | 4 |
| 24900709 | 10.1021/ml400049p | Unchecked | 3 |
| 24900709 | 10.1021/ml400049p | Sodium-dependent serotonin transporter | 3 |
| 25087753 | 10.1016/j.vascn.2014.07.002 | Voltage-gated inwardly rectifying potassium channel KCNH2 | 3 |
| - | 10.6019/CHEMBL4495565 | SARS-CoV-2 | 2 |
| 37468498 | 10.1038/s41467-023-40064-9 | Alpha-1A adrenergic receptor | 2 |
| - | 10.6019/CHEMBL4651402 | SARS-CoV-2 | 2 |
| 26948801 | 10.1016/j.drudis.2016.02.015 | Homo sapiens | 2 |
| 22112383 | 10.1124/dmd.111.043083 | Molecular identity unknown | 2 |
| 37468498 | 10.1038/s41467-023-40064-9 | Thromboxane A2 receptor | 2 |
| 25087753 | 10.1016/j.vascn.2014.07.002 | Voltage-gated potassium channel, IKs; KCNQ1(Kv7.1)/KCNE1(MinK) | 2 |
| 25087753 | 10.1016/j.vascn.2014.07.002 | Sodium channel protein type 5 subunit alpha | 2 |
| 25087753 | 10.1016/j.vascn.2014.07.002 | Voltage-dependent L-type calcium channel subunit alpha-1C | 2 |
| 37468498 | 10.1038/s41467-023-40064-9 | Muscarinic acetylcholine receptor M1 | 2 |
| 24900709 | 10.1021/ml400049p | Sodium-dependent noradrenaline transporter | 2 |
Data from ChEMBL 36 via Core Engine